Alemtuzumab 3-year data show durable effect on MS disability

A board to discuss the soon-to-be released drug Campath as a treatment for Multiple Sclerosis

Alemtuzumab 3-year data show durable effect on MS disability

Postby MSUK » Fri Oct 11, 2013 3:52 am

Latest data from the CARE-MS II extension study show that alemtuzumab (Lemtrada, Genzyme/Sanofi) has a durable effect on disability in multiple sclerosis (MS), with the mean Expanded Disability Status Scale (EDSS) score at 3 years still below that at baseline.<br><br>

These new data were presented in a poster at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) last week...... Read More - http://www.ms-uk.org/lemtrada
MS-UK - http://www.ms-uk.org/
User avatar
MSUK
Family Elder
 
Posts: 1985
Joined: Wed Oct 14, 2009 3:00 pm

Advertisement

Return to Campath (Lemtrada, Alemtuzumab)

 


  • Related topics
    Replies
    Views
    Last post

Who is online

Users browsing this forum: No registered users